FLSM
DAWN

Frazier Life Sciences Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Frazier Life Sciences Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-689,655
Closed -$8.74M – 50
2024
Q4 		$8.74M Hold
689,655
– – 0.36% 37
2024
Q3 		$9.61M Buy
+689,655
New +$9.84M 0.39% 40

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $589M AUM 9.29% 1-Year Est. Return

Frazier Life Sciences Management's DAWN Position: Q1 2025 in Review

Frazier Life Sciences Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2025, closing a stake of 689,655 shares — an estimated $8.74M sold.

Frazier Life Sciences Management first reported a position in DAWN in Q3 2024 and held it in 2 quarters. The position peaked at $9.61M in Q3 2024. 184 funds tracked by Wall St. Rank hold DAWN as of Q1 2025.

  • Frazier Life Sciences Management reported no remaining Day One Biopharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Frazier Life Sciences Management sold 689,655 Day One Biopharmaceuticals shares in Q1 2025, an estimated $8.74M.
  • Frazier Life Sciences Management first reported a position in Day One Biopharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Frazier Life Sciences Management's Day One Biopharmaceuticals position peaked at $9.61M in Q3 2024.
  • 184 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2025.

Based on Frazier Life Sciences Management's 13F filing for Q1 2025, filed 15 May 2025.